Up-Regulation of Plasminogen Activator Inhibitor-2 Is Associated With High-Risk HPV and Grade of Cervical Lesion at Baseline but Does Not Predict Outcomes of High-Risk HPV Infections or Incident CIN

作者：Syrjanen Stina; Naud Paulo; Sarian Luis; Derchain Sophie; Roteli Martins Cecilia; Longatto Filho Adhemar; Tatti Silvio; Branca Margerita; Erzen Mojca; Hammes Luciano S; Costa Silvano; Syrjanen Kari^*

来源：American Journal of Clinical Pathology, 2009, 132(6): 883-892.

DOI：10.1309/AJCPQQ07WUTZUTES

• High-risk human papillomavirus
• HPV
• Plasminogen activator inhibitor type 2
• PAI-2
• Serpin-B2
• Cytoplasmic
• Nuclear
• Cervical intraepithelial neoplasia
• CIN
• Baseline
• Viral outcomes
• Disease progression
• Longitudinal predictive values
• Surrogate end points

Protease inhibitor serpin-B2 (plasminogen activator inhibitor 2 [PAI-2]) protects pRb from degradation in human papillomavirus (HPV)-18+ HeLa cells. Our objective was to assess whether the pRb-mediated HPV-suppressive effect of PAI-2 in cancer cell lines has implications in the outcome of, HP V infections. Cervical biopsy specimens from 225 women were analyzed for PAI-2 expression to assess its value as a predictor of cervical intraepithelial neoplasia (CIN) grade, high-risk (HR) HPV at baseline, outcomes of HR-HPV infections, and the development of incident CIN.
PAI-2 expression increased in parallel with lesion grade. Nuclear PAI-2 expression was significantly related to HR-HP V detection and had a linear relationship with HR-HPV load PAI-2 expression was of no value in predicting the outcomes of HR-HPV infections. The same was true for PAI-2 as a predictor of surrogate end points (incident CIN 1+, CIN 2+) of progressive disease.
PAI-2 expression is up-regulated on transition from CIN 2 to CIN 3. The HR-HPV suppressive effects of PAI-2 were not related to more favorable outcomes of HR-HPV infections or lower risk of disease progression to CIN.

• 出版日期2009-12